Kumar adds
As with other GLP-1 agonists, retatrutide is likely to be unsuitable for those with a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
What is the pipeline for future medications for obesity
Pharmaceutical companies are aggressively investing in research and development, expanding the diabetes drug pipeline with novel therapies designed to manage blood sugar levels and promote weight loss
We also help patients understand GLP-1 coverage in California and insurance options when applicable
[DOI] [PMC free article] [PubMed] [Google Scholar] 138.Wharton S., Batterham R.L., Bhatta M., Buscemi S., Christensen L.N., Frias J.P., Jodar E., Kandler K., Rigas G., Wadden T.A., et al